2022CSH Lymphocyte Disease Special Session, 100 Schools of Thought, a Hundred Flowers Blooming! It lays a solid foundation for the precise treatment of lymphoma in the future

The 17th National Hematology Academic Conference of the Chinese Medical Association was grandly opened in Shanghai on September 23-25, 2022, with the theme of "respect, inheritance, collaboration and innovation", and invited well-known experts at home and abroad to talk about the latest progress
in the field of blood diseases.
In the special session on lymphocyte disease on the afternoon of the 24th, foreign scholars made special speeches and a number of domestic colleagues made paper speeches, and the
content was wonderful.

Professor He Pengcheng of the First Affiliated Hospital of Xi'an Jiaotong University and Professor Jin Zhengming of the First Affiliated Hospital of Soochow University served as the chairmen, and Professor Qiu Yuran of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Professor Zhang Lu of Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences and Professor Yu Ying of the Hematology Hospital of the Chinese Academy of Medical Sciences respectively delivered paper speeches
。 Professor Qiu Yuran said that at present, PTCL progress is rapid, the prognosis is poor, there is an urgent need to propose a more accurate and effective drug treatment plan for the disease, she and Professor Zhao Weiyuan's team conducted research on combined targeted therapy based on PTCL molecular classification, tested the genetic mutation of patients and obtained innovative molecular classification by category, and selected combined targeted drugs as a supplement to existing chemotherapy regimens according to molecular classification, and the data has not yet been published
。 Professor Zhang Lu introduced a national multicenter registered study on the diagnosis and treatment status of patients with Castleman disease (CD), which depicted the disease status, treatment options and prognosis of CD patients in China, and for the first time validated the concept
of "heavy iMCD" proposed by the Chinese Castleman Disease Collaborative Group (CDNC) in a large cohort 。 Professor Yu Ying introduced a clinical report of Chinese single-center Fahrenheit macroglobulinemia patients (WM) patients with "Clinical features, treatment options and recurrence patterns of Chinese single-center Fahrenheit macroglobulinemia patients", in the past three decades, the treatment mode of WM has undergone a major change, and the application of new drugs such as rituximab has brought survival improvement to WM patients, but the treatment options of WM patients still need to be further explored
.

Professor Li Caixia of the First Affiliated Hospital of Soochow University and Professor Cui Guohui of the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology served as the chairmen, and Professor Zou Hesong of the Hematology Hospital of the Chinese Academy of Medical Sciences and Professor Shen Ye of the First Hospital of Peking University respectively delivered paper speeches
.
Professor Zou Hesong introduced a real-world efficacy analysis of prognostic stratified treatment for patients with single-center young diffuse large B-cell lymphoma (DLBCL) in China, and the results showed that the real-world prognostic stratification treatment strategy significantly improved the survival of young DLBCL patients and outperformed the historical data
of R-CHOP therapy 。 Professor Shen Ye introduced a single-center retrospective study, the results of which showed that the 5-hydroxymethylcytosine (5hmC) changes in plasma free DNA can not only be used for the minimally invasive diagnosis of DLBCL, but also can be used to determine the primary site, and more plasma and tissue samples need to be included in the future, analyze the 5hmC changes in patients with different primary sites of DLBCL, and explore its potential biological significance
.

Professor Bai Ou of the First Hospital of Jilin University and Professor Xu Jingyan of the Affiliated Drum Tower Hospital of Nanjing University School of Medicine served as the chairmen, and Professor Yu Qiuxia of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology and Professor Liu Hailing of Jiangsu Provincial People's Hospital respectively delivered paper speeches
.
Professor Yu Qiuxia introduced a single-center study of radiotherapy bridging CD19/22 CAR-T cell therapy for relapsed/refractory B-cell lymphoma, which showed that radiotherapy bridging CD19/22 CAR-T treatment did not have serious toxic side effects beyond expectations, and could reduce the incidence
of severe CRS.
Radiation therapy as a bridging treatment strategy before CAR-T can significantly increase a patient's ORR for 30 days and improve a patient's PFS compared to chemotherapy
.
Professor Liu Hailing introduced a single-armed, multicenter, phase II study of tiralizumab combined with GemOx in the treatment of relapsed refractory Hodgkin lymphoma, and the results showed that for patients with R/R cHL, the combination of tirelizumab and GemOx had good efficacy and safety, and in the absence of ASCT consolidation, tiralizumab maintenance provided long-lasting relief
for patients with R/R cHL.

Professor Yang Shenmiao of Peking University People's Hospital and Professor Ding Kaiyang of Anhui Provincial Cancer Hospital served as the chair, and Professor Sha Yeqin of Jiangsu Provincial People's Hospital and Professor Ding Mengfei of Shandong Provincial Hospital respectively delivered paper speeches
.
Professor Sha Yeqin's team identified IGHV fragments and V-D-J rearrangement patterns before and after Richter conversion DLBCL transformation, and clarified the cloning homology of
patients with Richter conversion DLBCL.
The evolution mode of Richter transformation DLBCL clone was inferred using high-depth NGS sequencing dynamic detection, suggesting that TP53, NOTCH1, and EGR2 mutations in Asian populations were important risk factors
for Richter transformation 。 Professor Ding Mengfei introduced a research result of his and his team, which suggested that NAT10 plays a carcinogenic role in DLBCL, NAT10 regulates the stability of SLC30A9 mRNA through ac4C modification-dependent methods, and NAT10 regulates SLC30A9 mediates the AMPK signaling pathway and promotes the development
of DLBCL.

Professor Wang Xiaobo of the Second Affiliated Hospital of Dalian Medical University and Professor Shi Wenyu of the Affiliated Hospital of Nantong University served as the chairmen, and Professor Wang Hui of Shandong Provincial Cancer Hospital and Professor Yu Yehua of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine respectively delivered paper speeches
.
Professor Hui Wang introduced a prospective clinical study from multiple centers, the results of which showed that patients with inert non-Hodgkin lymphoma or elderly mantle cell lymphoma in China with inert non-Hodgkin lymphoma or elderly mantle cell lymphoma with benzamustine combined with rituximab (with or without lenalidomide maintenance therapy) had good efficacy and safety in
the medium term, and follow-up was still ongoing 。 Professor Yu Yehua introduced the clinical features and prognosis analysis of oral and maxillofacial DLBCL, oral and maxillofacial DLBCL patients have early stages, low IPI score, but the prognosis is not better than that of patients with non-oral and maxillofacial onset, and non-Merriamb-Webster ring onset is an important reason for
the poor prognosis of oral and maxillofacial DLBCL.

Professor Liu Hui of Beijing Hospital and Professor Fu Jianfei of Shanghai Tongji Hospital served as the chair, and Professor Zhang Muchen of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine and Professor Zhou Lili of Shanghai Tongji Hospital made speeches respectively
.
Professor Zhang Muchen introduced that decitabine combined with R-CHOP regimen is effective in the treatment of TP53 mutation DLBCL, and a multi-center clinical study with a larger sample size is being carried out nationwide, and then further explore the mechanism
of action of combination therapy on TP53 mutation DLBCL.
Professor Lili Zhou introduced a single-center retrospective analysis to explore the platelet reduction after CAR-T cell therapy for B-cell tumors, and the results showed that the platelet < of 50×109/L in lymphoma patients after CAR-T cell therapy was significantly later than that in leukemia patients, and the EFS in patients with platelet ≥ 50×10⁹/L after CAR-T treatment was significantly better than that in platelet <50×¹⁰⁹ /L patients
.

Professor Huang Honghui of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Professor Huang Haiwen of the First Affiliated Hospital of Soochow University served as the chairmen, and Professor Wang Liang of Beijing Tongren Hospital Affiliated to Capital Medical University and Professor Wang Jie of West China Hospital of Sichuan University respectively delivered paper speeches
.
Professor Wang Liang introduced an open-label, prospective, single-center, Phase II study, which showed that BTK inhibitors can quickly penetrate the blood-eye barrier and have good efficacy and safety
against vitreoretinal lymphoma (VRL).
The disease control time of BTK inhibitors on VRL and PCNSL needs to be further extended, and the combination with traditional protocols is worth exploring
.
Professor Wang Jie introduced a new highly selective HDAC inhibitor Puisostat mesylate in the treatment of recurrent or refractory lymphoma dose-increasing Phase I clinical trial, the preliminary results showed good safety, according to the current trend of good tolerability, has climbed the gradient to 15mg/^m2 dose group, will soon start phase II clinical trials
.

Professor Li Hao of Qilu Hospital of Shandong University and Professor Hu Yongxian of the First Affiliated Hospital of Zhejiang University School of Medicine served as the chairmen, and Professor Zhu Ying of the First Affiliated Hospital of Soochow University and Professor Shen Ziyuan of the Affiliated Hospital of Xuzhou Medical University respectively made paper speeches
.
Professor Zhu Ying said that for patients with R/R DLBCL who have failed CAR-T treatment, their treatment faces great challenges
.
Vinekra-based combination therapies provide a new treatment strategy and basis
for patients with R/R DLBCL who have failed CAR-T therapy.
Through retrospective analysis of ENKTL data from multiple centers in China, Professor Shen Ziyuan's team established the HHLWG-NPI prognostic model, which can accurately stratify
the prognosis of current ENKTL patients.
In addition, HHLWG-NPI is better able to identify real, high-risk patients
than PINK, KPI, and IPI systems.

Professor Liu Tingbo of Union Hospital Affiliated to Fujian Medical University and Professor Yu Wenjuan of the First Affiliated Hospital of Zhejiang University School of Medicine served as the chairmen, and Professor Wu Yunpeng of the Cancer Hospital of the Chinese Academy of Medical Sciences, Professor Rao Jun of the Second Affiliated Hospital of the Army Military Medical University (Xinqiao Hospital) and Professor Yang Zailin of the Affiliated Cancer Hospital of Chongqing University respectively made paper speeches
。 Professor Wu Yunpeng introduced that "the survival differences of different primary parts of early non-gastric MALT lymphoma are related to the proportion of radiotherapy", and the proportion of radiotherapy for cutaneous MALT lymphoma is higher and the prognosis is better, while the proportion of radiotherapy for pulmonary MALT lymphoma is low (lack of recognized and safe radiotherapy methods), and the prognosis is poor
.
In the future, safer and more effective radiotherapy strategies need to be established, and patients with primary lung MALT lymphoma should consider radiation therapy
more aggressively.
Professor Rao's team conducted a study using the expression characteristics of transporting RNA-derived small RNA (tsRNA) as a biomarker for the prediction and prognosis of DLBL, which for the first time systematically elaborated the differential expression profile of small non-coding RNA (sncRNA) between DLBCL and peripheral serum in healthy volunteers.
A new model for risk prediction of patients with DLBCL was created, which guides patients in prognosis; The new model has potential clinical application advantages for the early diagnosis of lymphoma patients, but it needs to be validated
by large sample studies.
Professor Yang Zailin introduced the analysis of the results of the high-frequency mutation genetic detection of HIV-related lymphoma with the title of "Genetic Detection and Clinical Significance Analysis in HIV-related Lymphoma", and further research is needed, and the sample size is expanding, and it is necessary to conduct correlation analysis
based on treatment, disease progression and prognosis outcome.

Professor Zhou Zhenhai of the First Affiliated Hospital of Sun Yat-sen University and Professor Xu Bing of the First Affiliated Hospital of Xiamen University served as the chairmen, and Professor Zhou Keshu of Henan Provincial Cancer Hospital, Professor Liu Hui of the Second Affiliated Hospital of Zhejiang University School of Medicine, and Professor Lu Yaxiao of Tianjin Cancer Hospital respectively delivered paper speeches
。 Professor Zhou Keshu introduced a Phase II clinical study (LOTIS-2) in which the overall health status and health-related quality of life (HRQOL) of high-risk DLBCL patients remained stable or improved during the treatment phase of Lonca, and patients in the high-risk group tolerated treatment well, even better than other patients, and the results of this study further supported the application
of Llonca in patients with high-risk R/R DLBCL 。 Professor Liu Hui introduced the research he and his team conducted in the application of IL-7 and CCL19 CAR-T cells in patients with recurrent or refractory large B-cell lymphoma, with good
initial safety and efficacy.
Professor Yaxiao Lu introduced his and his team's research results with the title of "TP53 and CD58 gene mutant mutual exclusion patterns and unique immune microenvironment characteristics in DLBCL", and the TP53 mutation status alone is not enough to effectively distinguish the prognosis of DLBCL patients, TP53 and CD58 mutation mutual exclusion modes can accurately stratify
DLBCL patients.

At the end of this special session, Professor Shen Lin of Huadong Hospital affiliated to Fudan University concluded that the conference was full of dry goods, and many speakers made detailed introductions from basic research to translational research to clinical research, laying a good foundation
for the accurate treatment of tumors in the future.
At this point, the special meeting of the lymphocyte disease group came to a successful conclusion
.

Poke "Read the original article" and go to the micro-official website to get more meeting information